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Erythropoietin levels in the different clinical forms of hereditary
spherocytosis
Hereditary spherocytosis (HS) is the most common red cell
membrane disorder affecting one in 2500 individuals of
northern European ancestry (Bolton-Maggs et al, 2004). It is
a congenital haemolytic anaemia that is dominantly inherited
in 75% of cases, the remaining cases show a recessive or non-
dominant pattern of inheritance, such as spontaneous de novo
mutations, which are often caused by family-specific private
mutations (Agre et al, 1986; Eber et al, 1990; Miraglia del
Giudice et al, 1998).
Hereditary spherocytosis is highly heterogeneous in terms of
clinical and laboratory presentation, ranging from an asymp-
tomatic condition to a severe life-threatening transfusion-
dependent anaemia (Bolton-Maggs et al, 2004). According to
haematological and clinical presentation, HS is usually classi-
fied as mild, typical or moderate, and severe (Bolton-Maggs
et al, 2004). The presence of spherocytes in the peripheral
blood smear, the increase in red blood cell (RBC) osmotic
fragility and reticulocytosis are hallmarks of HS (Iolascon et al,
1998).
The erythrocytes in HS, by loosing membrane surface area,
undergo a spherocytic shape change and a reduction in their
deformability. These changes are because of defects in RBC
membrane proteins, including ankyrin, band 3, spectrin and
protein 4Æ2. The increased rigidity of the cell membrane leads
to premature spleen trapping and destruction of spherocytes,
causing the haemolysis experienced by these patients. The
clinical manifestations of HS are, therefore, usually abrogated
by splenectomy (Tse & Lux, 1999).
In healthy humans, erythropoiesis counterbalances the
continuous removal of aged RBCs. About 1% of circulating
RBCs are destroyed daily and replaced by reticulocytes.
Erythropoietin (EPO) is the main growth factor responsible
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Summary
Erythropoietin (EPO), the main growth factor responsible for the regulation
of red blood cell production, may be overproduced when blood loss or
haemolysis occurs. Patients with mild hereditary spherocytosis (HS) are able
to maintain normal haemoglobin concentration, whereas typical and severe
HS patients develop an anaemic state. Splenectomy usually reverses anaemia.
We aimed to clarify the role of EPO in the response to enhanced spherocyte
destruction, and to look for a linkage with the broad clinical spectra of HS.
EPO levels, reticulocyte count and production index (RPI), other parameters
used to classify HS and the protein deficiencies underlying HS were evaluated
in previously diagnosed unsplenectomised (n ¼ 24) and splenectomised
(n ¼ 10) patients presenting mild, typical or severe HS. A significant increase
in EPO was observed in all unsplenectomised HS patients. In the mild form, a
significant correlation of EPO with reticulocyte count and RPI was observed;
however, this correlation disappeared in typical HS patients. Splenectomised
HS patients presented a correction in EPO levels in all forms of HS, although
the reticulocyte count and RPI sustained slightly higher values. Our data
show HS as a disease linked to an overproduction of EPO, according to the
severity of the disease; however, a disturbance in erythropoiesis seems to
occur in typical HS. Moreover, splenectomy leads to a correction in the EPO
levels.
Keywords: hereditary spherocytosis, erythropoietin, erythropoietin response,
outcome of hereditary spherocytosis.
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for the regulation of RBC production in steady-state condi-
tions and for enhancing the production rate of RBCs,
whenever blood loss or haemolysis occurs (Krantz, 1991;
Jelkmann, 1992). Besides the kidney, which is the main site of
production in the adult, additional organs and cells, including
liver, uterus, endothelial cells, vascular smooth muscle cells
and insulin-producing cells have been found to secrete EPO
(Fisher, 2003; Maiese et al, 2005).
The primary stimulus for increasing EPO synthesis is tissue
hypoxia resulting from reduced blood oxygen availability. By
inducing EPO gene expression and synthesis, hypoxia leads to
a rise in the plasmatic levels of EPO (Ebert & Bunn, 1999). In
the bone marrow, the erythroid progenitor cells, erythroid
burst-forming units (BFU-E) and erythroid colony-forming
units (CFU-E), present specific receptors for EPO on their
surface. When EPO binds to the receptors on these cells, they
proliferate and develop into erythroblasts and, finally, to
reticulocytes that enter the peripheral circulation and will
mature into RBC (Lappin, 2003).
When the reticulocytes are released normally from the bone
marrow, remaining in circulation for the normal period of
time for maturation into erythrocytes (about 24 h), the
number of circulating reticulocytes is an accurate reflection
of the erythropoietic activity. However, under an erythro-
poietic stimulus, reticulocytes are prematurely released and the
maturation time of the ‘stressed’ reticulocytes in the peripheral
blood may be as long as 3 days. In this case, the reticulocyte
count needs to be corrected for both changes in haematocrit
(degree of anaemia) and in the effect of EPO on premature
reticulocyte release from the bone marrow. Considering the
common features in HS patients (anaemia and reticulocytosis),
we have calculated the reticulocyte production index (RPI) as
an appropriate way to measure the effective RBC production
(Hillman & Ault, 2002).
Patients with mild HS, despite the increased RBC destruc-
tion, are able to maintain a normal haemoglobin concentra-
tion, probably on account of the physiologically increased EPO
synthesis and erythroid expansion. However, in moderate and
severe HS an anaemic state develops, suggesting a disturbance
in that physiological mechanism.
Splenectomy of HS patients is usually effective in reducing
haemolysis and improving the anaemia by leading to a
significant prolongation of the RBC life span, though not
always to a normal value (Chapman & McDonald, 1968; Baird
et al, 1971). Since splenectomy abrogated the clinical mani-
festations, the diagnosis of HS was likely to lead to splenec-
tomy irrespective of the severity of HS, for several years, and
explains why some mild and typical HS patients were
splenectomised (Zinkham, 1969). Nowadays, patients are
selected for splenectomy on the basis of their age, clinical
symptoms and presence of complications, such as gallstones
(Bolton-Maggs et al, 2004).
The erythrocyte membrane protein deficiencies underlying
HS are usually identified by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) of membrane
proteins (Bolton-Maggs et al, 2004). The same protein defi-
ciency may account for a mild, typical or severe presentation of
the disease. It is accepted that the most commonly affected
proteins are ankyrin and band 3 protein, and less frequently
spectrin and protein 4Æ2 (Miraglia del Giudice et al, 1994;
Lanciotti et al, 1997). We recently reported that band 3 and
ankyrin deficiencies are the major causes for HS in a
Portuguese studied sample (Rocha et al, 2005).
In this study, the plasmatic EPO levels of unsplenectomised
HS patients presenting a mild or a typical form of HS, and
splenectomised HS patients presenting a mild, typical or severe
HS were evaluated, in order to clarify the role of EPO in the
physiological response to enhanced spherocyte destruction and
to look for a connection to the broad haematological and
clinical spectra of the disease and to the underlying erythrocyte
membrane protein deficiencies. Moreover, we also evaluated
the EPO response after splenectomy according to severity of
HS.
Materials and methods
Subjects
We studied 56 individuals from the north of Portugal: 22
controls, 18 patients with mild HS (three were splenectom-
ised), 13 patients presenting typical HS (four were splenec-
tomised) and three splenectomised patients with severe HS.
The control group included three children, 15 adults and four
elderly; the mild HS group included 10 children and eight
adults; the typical HS group included seven children and six
adults and the severe HS patients included two children and
one adult. We used children in this study because it is in
childhood that the disease is usually diagnosed, with the severe
cases recommended for splenectomy at an appropriate age. We
felt, therefore, that children should be a good target group to
study, in order to assemble all forms of the disease. Actually,
many HS adult patients with typical and severe HS are
splenectomised and, therefore, could not meet all of our
proposed aims. We included in all groups of patients a similar
number of children and adults, and no elderly were included.
Patients who had undergone splenectomy had been sub-
mitted to surgery more than 1 year before this study.
The 34 HS patients were previously diagnosed and classified
as presenting mild, typical or severe HS, according to
haematological and biochemical data, and clinical follow-up.
The membrane protein deficiency underlying HS was identi-
fied and quantified for all patients by electrophoretic analysis
of RBC membrane proteins.
Unsplenectomised patients with the mild form of the disease
were asymptomatic, showing a mild compensated haemolysis;
typical HS patients presented a mild to moderate anaemia and
the severe HS patients presented a transfusion-dependent
anaemia. The haematological and biochemical criteria used for
classification were those of Bolton-Maggs et al (2004). The
haematological and biochemical values presented are those
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shown by the individuals at time of blood collection for the
present studies.
In the case of severe HS patients, there was no contamin-
ation with transfused blood, as the last transfusion took place
at least 4 months before the collection of blood for our studies.
All severe HS patients were splenectomised. Three HS patients
classified as mild had been splenectomised in adulthood, as
they developed a symptomatic vesicular litiasis. None of the
controls and patients presented chronic inflammatory diseases,
abnormal renal function or iron and folic acid deficiencies, at
time of blood collection.
Assays
Blood samples [ethylenediaminetetraacetic acid (EDTA) and
heparin as anticoagulants] were collected and processed for the
haematological and biochemical analysis. To exclude immune
haemolysis a direct antiglobulin test was performed for all
studied cases (Regan et al, 2001).
We evaluated the RBC count, haemoglobin concentration,
the red cell distribution width (RDW), mean cell haemoglobin
(MCH) and mean cell haemoglobin concentration (MCHC),
by using an automatic blood cell counter (Sysmex K1000,
Sysmex, Hamburg, Germany).
The search for spherocytic cells was performed in Wright
stained blood films (International Committee for Standardi-
sation in Haematology, 1984). Osmotic fragility test was
carried out on fresh blood and after 24 h of incubation at 37C
(Roper et al, 2001). Serum concentration of total bilirubin was
measured by routine biochemical procedures.
Reticulocyte count was performed by microscopic counting
on blood smears after vital staining with new methylene blue
(Reticulocyte stain; Sigma, St Louis, MO, USA). Considering
the common features in HS patients – anaemia and reticul-
ocytosis – we have calculated the reticulocyte production index
(RPI) as an appropriate way to measure the effective RBC
production (Hillman & Ault, 2002). Plasma was separated after
centrifugation and EPO plasma levels were evaluated by an
enzyme-linked immunosorbent assay (Human EPO Quanti-
kine IVD ELISA Kit; R&D Systems Inc, Minneapolis, MN,
USA).
To prepare the RBC membranes for electrophoretic analysis,
plasma and leucocytes were previously isolated from RBCs and
discarded after centrifugation on a double density gradient
(Histopaque 1Æ077 and 1Æ119; Sigma). RBCs were washed in
saline solution. The erythrocytes were lysed by hypotonic lyses
according to Dodge et al (1963). The obtained membranes
were washed in Dodge buffer, with phenylmethylsulphonyl
fluoride added as a protease inhibitor, in the first two washes,
with a final concentration of 0Æ1 mmol/l. The protein concen-
tration of the RBC membrane suspensions was determined by
the Bradford method (Bradford, 1976).
The electrophoretic analysis of the red cell membrane
proteins was carried out on a discontinuous SDS-PAGE, using
a 5–15% linear acrylamide gradient gel and a 3Æ5–17%
exponential acrylamide gradient gel, according to Laemmli
(1970) and Fairbanks et al (1971), respectively. The proteins
were stained with Coomassie brilliant blue, and scanned
(Darkroom CN UV/wl; BioCaptMW, version 99; Vilber
Lourmat, Marne-La-Valle´e, France). The relative amount of
each major protein (as a percentage of total), was quantified by
densitometry (Bio1D++, version 99; Vilber Lourmat).
The electrophoretic analysis for each RBC membrane sample
was performed in duplicate gels, and, in each gel, duplicates of
each sample were loaded alongside with six control samples.
The mean values presented by the studied subjects were
compared with those presented by the control samples. A
protein deficiency was considered significant whenever the
mean value of that protein was lower than the mean value
minus 2 · SD presented by the control samples for the same
protein (subject mean protein % value < control mean protein
% value )2 · SD).
Statistical analysis
Measurements are presented as mean ± SD or as median
values (inter-quartile range). For statistical analysis, we used
the Statistical Package for Social Sciences (spss, version 12.0,
SPSS Inc, Chicago, IL, USA) for Windows. To evaluate the
differences between groups, we used the Student’s t-test
whenever the parameters presented a Gaussian distribution
and the Mann–Whitney test in the case of a non-Gaussian
distribution. Spearman’s rank correlation coefficient was used
to evaluate relationships between sets of data. A P-value lower
than 0Æ05 was considered as statistically significant.
Results
In Table I, we present the haematological values for controls
and HS patients, according to the severity of the disease. For
each form of the disease, we present the results for unsple-
nectomised and splenectomised patients. We observed that, in
unsplenectomised patients, worsening of the disease was
associated with a reduction in RBC count, Hb concentration
and haematocrit, and a rise in MCHC, RDW, and in osmotic
fragility. In splenectomised HS patients, we found a correction
for all those parameters, except for MCHC and the osmotic
fragility, which sustained a higher value when compared with
controls, and, actually, presented a trend to rise with severity of
the underlying disease.
The bilirubin levels (Table II) increased with worsening of
the disease and reached significantly higher values in typical
HS unsplenectomised patients. Splenectomised HS patients
showed a reduction in these values, though sustaining a trend
to higher values, when compared with controls.
Concerning EPO (Table II; Fig 1A), we found a significant
increase with the severity of the disease in HS unsplenectom-
ised patients. The median values in mild HS patients were
double those of the control values, and in the case of typical
HS patients, they presented almost an eightfold increase when
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compared with the control values. In splenectomised HS
patients the values had been corrected by splenectomy.
Considering the reticulocyte count and RPI, reflecting the
rate of RBC production, we found that in HS unsplenectom-
ised patients (Table II; Fig 1B and C) the reticulocyte count
increased significantly with the severity of the disease and the
same occurred for RPI, though the rise observed for typical HS
patients in RPI was not as striking as that observed in mild HS,
in which the values were double those of the control. When
comparing these EPO levels, reticulocyte count and RPI
presented by unsplenectomised patients with mild and typical
HS, we found significantly different values for EPO (P < 0Æ01)
(Fig 1A) and for reticulocyte count (P < 0Æ05) (Fig 1B), but
not for RPI (Fig 1C).
The 34 studied HS patients showed different erythrocyte
membrane protein deficiencies underlying the disease
(Table III). In 26 patients an isolated band 3 or combined
with protein 4Æ2 deficiency was observed; 17 had mild HS,
eight typical HS and one severe HS. An ankyrin and/or
combined spectrin and protein 4Æ2 deficiencies was found in
one case of mild HS and two of typical HS. In four patients
with spectrin deficiency, two of them presented as typical HS
and the others as severe HS. A case of protein 4Æ2 deficiency
was also observed, presenting as typical HS.
Concerning splenectomised patients, a correction for EPO
was observed in all forms of the disease; a higher reticulocyte
count and RPI than controls was observed in mild, typical and
severe patients.
Looking for the relationship between the erythropoietic
stimulus and the effective RBC production in accordance with
the severity of the disease, we studied the correlation of EPO
levels with reticulocyte count and RPI in unsplenectomised
mild and typical HS patients. Mild HS patients (Fig 2) showed
a significant positive correlation between EPO and the
reticulocyte count (r ¼ 0Æ825; P < 0Æ001), as well as with RPI
(r ¼ 0Æ757; P < 0Æ01). However, no significant correlations
were observed between EPO and reticulocyte count
(r ¼ 0Æ200), as well as with RPI (r ¼ 0Æ117) for typical HS
patients (Fig 3).
We also looked for a connection between the type of protein
deficiency and EPO levels in mild and typical HS unsplenec-
tomised patients (Fig 4). We found that in typical HS patients
presenting a primary ankyrin deficiency, the EPO levels were
higher than the median values observed in controls and in mild
unsplenectomised HS patients. The same occurred for the two
studied cases of spectrin deficiency presenting a typical HS.
However, for primary band 3 deficiency with typical HS, we
found that in three of the five studied cases, the EPO levels
were within the values observed for controls (one case) and
mild (two cases) unsplenectomised HS patients.
Discussion
The membrane pathology in HS is effected by a change in cell
shape from the deformable biconcave disc into a spherocyticT
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poorly deformable cell, seen on the blood smears as sphero-
cytes. The vertical and horizontal interactions between mem-
brane constituents account for the integrity, strength and
deformability of the cell. Disruptions of vertical interactions,
because of membrane protein deficiencies, favour membrane
vesiculation and, therefore, the development of spherocytes.
Hereditary spherocytosis occurs in most racial groups, is the
commonest cause of inherited chronic haemolysis in the
Northern Europe and usually presents an autosomal inherit-
ance pattern. It was described in 1871 and, since then, much
has been clarified about the structure of the red cell membrane
and the genetic defects causing HS. However, some contro-
versies still exist about the clinical outcome of the disease. It
presents a clinical broad spectrum, being usually classified as
mild, typical or moderate and severe, according to clinical and
analytical follow-up. Although the clinical severity of HS
differs among families, it is quite similar within a family
presenting an autosomal pattern of inheritance (Eber et al,
1990; Iolascon et al, 1998). The differences in HS clinical
expression within a family have been ascribed to a heterozy-
gous combination of interacting alleles, a common allele and a
weak allele and to a coinheritance of another erythrocyte
disorder, able to affect HS phenotype (Alloisio et al, 1996,
1997). The mechanism underlying the heterogeneous clinical
outcome of the disease among families is, also, still poorly
clarified. The same type and amount of the primary protein
deficiency underlying HS may present a different clinical
expression. Recently, we reported that similar values of protein
deficiencies in the deficient proteins (primary and secondary)
was observed in mild HS patients, while in typical and severe
HS a trend to an unbalance was found, suggesting the
importance of a balanced interaction between proteins in the
clinical outcome of the disease (Rocha et al, 2005). Some
authors have reported a relationship between clinical severity
of HS with specific membrane protein defects (Miraglia del
Giudice et al, 1994), and others with the quantitative defici-
ency in spectrin, even when it is secondary to a primary
deficiency in another membrane protein (Agre et al, 1986).
Moreover, the severity of the disease is closely associated with
the severity of haemolysis and spleen size.
In accordance with the literature (Iolascon et al, 1998;
Bolton-Maggs et al, 2004), we observed that in unsplenectom-
ised HS patients, worsening of the disease was associated with a
reduction in RBC count, Hb concentration and haematocrit,
and a rise in MCHC, RDW, and in osmotic fragility (Table I).
These changes were associated with an increased haemolysis, as
suggested by the rise in bilirubin levels (Table II). The
haemolytic reduction in the number of circulating RBCs,
leading to a reduction in tissue oxygen delivery, triggers the
physiological mechanism to compensate this condition, by
enhancing EPO production to stimulate erythropoiesis. Actu-
ally, we observed an erythropoietic stimulus, as shown by the
increase in the EPO levels, in reticulocyte count and in the RPI
(Table II; Fig 1A–C). In unsplenectomised mild HS patients
the median levels of EPO were double those of the control
values and the same occurred for reticulocyte count and for
RPI. In typical unsplenectomised HS patients, the significantly
higher haemolysis, as shown by the significant increase in
bilirubin concentration, was associated to a rise in EPO levels
that was almost quadruple those presented by mild HS
patients. However, this erythropoietic stimulus was not
paralleled by a similar effective reticulocyte production.
Typical unsplenectomised HS patients presented a median
reticulocyte count value, which was only 2Æ5-fold the value of
the mild unsplenectomised HS patients, and the median value
of RPI was similar to those presented by the mild unsplenec-
tomised HS patients. Considering the overlap between the
error bars for reticulocyte count and for RPI between the mild
and typical groups (Fig 1B and C), as well as the small number
of typical unsplenetomised HS patients, we removed the
outliers in this group, and found no substantial effect in the
statistical results, nor in the subsequent conclusions.
To clarify the results, we studied the correlations between
EPO levels and the effective reticulocyte production. We found
that in mild HS a significant positive correlation was observed
between stimulus and effective erythropoietic response (Fig 2);
Table II. Biochemical and haematological data for controls and HS patients according to severity of HS.
Group Bilirubin (lmol/l) Erythropoietin (mUI/ml) Reticulocytes (109/l) RPI
Controls (n ¼ 22) 8Æ80 (5Æ83–13Æ4) 9Æ68 (7Æ58–11Æ6) 67Æ4 (55Æ8–96Æ3) 1Æ43 (1Æ18–1Æ86)
Mild HS (n ¼ 18)
15 unspl. 9Æ00 (6Æ66–36Æ0) 19Æ7 (7Æ58–42Æ0)* 156 (91Æ6–287)*** 2Æ84 (1Æ54–4Æ69)**
3 spl. 19Æ0 (10Æ2–27Æ6) 8Æ70 (5Æ29–12Æ9) 91Æ1 (90Æ0–108) 1Æ85 (1Æ80–2Æ04)
Typical HS (n ¼ 13)  
9 unspl. 34Æ7 (14Æ0–106)** 72Æ2 (34Æ3–108)*** 380 (233–509)*** 2Æ96 (2Æ62–6Æ20)***
4 spl. 17Æ0 (11Æ0–24Æ5) 8Æ27 (6Æ18–10Æ0) 141 (108–158)** 2Æ92 (2Æ00–2Æ99)**
Severe HS (n ¼ 3)
3 spl. 13Æ1 (7Æ42–18Æ8) 11Æ2 (8Æ40–14Æ8) 127 (66Æ2–156) 1Æ83 (1Æ12–2Æ58)
Data are presented as median (IQR) values.
no spl., unsplenectomised; spl., splenectomised.
***P < 0Æ001; **P < 0Æ01; *P < 0Æ05 (HS versus control).
P < 0Æ001; P < 0Æ01; P < 0Æ05 (no spl. versus spl.).
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however, in typical HS the same was not observed, suggesting a
failure or a disturbance in the response mechanism, despite the
significantly higher erythropoietic stimulus (Fig 3).
As far as we know, only Guarnone et al (1996) have reported
an over production of EPO in compensated and anaemic HS
patients (some of them were splenectomised), and suggested
this feature as a biological characteristic of the disease. Our
data, in agreement with this report, shows high levels of EPO
in all unsplenectomised HS patients, whatever the severity of
the disease. This overproduction of EPO reflects the adaptive
response to tissue hypoxia resulting from enhanced and
premature RBC removal.
Moreover, we found that the balance between the erythro-
poietic stimulus and the effective production of reticulocytes
observed in mild patients was no longer observed in typical HS
patients. The significantly higher levels of EPO in typical HS
patients were not able to induce the expected reticulocyte
production.
All the major events involved in RBC development, survival,
growth and maturation are maintained by EPO binding to the
receptors of the maturating erythroid cells (Lappin, 2003).
These receptors appear gradually along the maturation of
progenitor cells, and begin to disappear with the onset of
haemoglobin synthesis in the early erythroblast (D’Andrea &
Zon, 1990; Remy et al, 1999). Afterwards, the rate of prolif-
eration will be mainly determined by the availability of the
erythropoietic nutrients, iron, vitamin B12 and folic acid.
It is known that in chronic diseases associated with
inflammatory processes, the release of cytokines (tumour
necrosis-factor, interferon-gamma) may affect erythropoiesis,
inducing usually a mild to moderate anaemia. The more likely
explanation for the development of this anaemia is a decreased
production and/or action of EPO. Cytokines involved in the
inflammatory response may inhibit both EPO synthesis and
erythroid colony formation (Faquin et al, 1992; Means &
Krantz, 1992), as well as downregulate the EPO receptor at the
surface of the progenitor erythroid cells (Taniguchi et al, 1997).
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Table III. Protein deficiency and clinical classification.
Spectrin
deficiency
Ankyrin and/
or combined
spectrin and
protein 4Æ2
deficiencies
Isolated band
3 or combined
with protein
4Æ2 deficiency
Protein 4Æ2
deficiency
Mild HS
spl. – – 3 –
unspl. – 1 14 –
Typical HS
spl. – – 3 1
unspl. 2 2 5 –
Severe HS
spl. 2 – 1 –
Total 4 3 26 1
unspl., unsplenectomised; spl., splenectomised.
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In HS, the reduced deformability of the RBCs imposes an
enhanced spherocyte sequestration and removal by the macro-
phages of the reticulo-endothelial system. We speculated if in
HS, as occurs in chronic diseases, this enhanced macrophage
activation could be involved in the inhibition of EPO synthesis
and/or of the EPO response, as seems to occur with worsening
of the disease. Another possible explanation for the inhibition
of EPO response could involve the EPO receptors, which may
be lacking or presenting an impaired transduction signal,
possibly also because of the inflammatory cytokines and
breakdown products of dead or dying cells (Erslev, 2001).
Strengthening the hypothesis of the involvement of inflam-
matory cytokines in the inhibition of EPO response with
worsening of HS, we found that the EPO levels were corrected
after splenectomy, although the reticulocyte count and the RPI
could still sustain higher values. Splenectomy, by reducing
RBC removal and, therefore, macrophage activation seems to
allow, thereafter, an appropriate EPO response.
The electrophoretic analysis of the erythrocyte membranes
(Table III) showed that isolated band 3 or combined with
protein 4Æ2 deficiency was the major cause for HS, and that
spectrin deficiency and ankyrin and/or combined spectrin and
protein 4Æ2 deficiencies presented a similar prevalence in the
studied group (n ¼ 4 and n ¼ 3, respectively). Only one case
of protein 4Æ2 deficiency was observed. These results are
slightly different from those, we recently reported for a larger
sample of Portuguese HS patients (Rocha et al, 2005), in which
the major cause for HS was a primary band 3 deficiency,
followed by primary ankyrin deficiency and spectrin defici-
ency. The differences are probably the result of the different
size of the studied groups. The search for a connection between
EPO levels and the type of protein deficiency underlying HS
(Fig 4), showed that in typical HS patients both with a primary
ankyrin deficiency and with a spectrin deficiency, the EPO
levels were higher than the values observed in controls and in
mild unsplenectomised HS patients. However, for primary
band 3 deficiency with typical HS, we found that in three of the
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five studied cases, the EPO levels were within the values
observed for controls (one case) and for mild (two cases)
unsplenectomised HS patients. We may speculate if, in this
type of protein deficiency, an inhibition of EPO synthesis may
occur instead of an inhibition of the EPO response, as seems to
occur in the other types of protein deficiencies. However, this
hypothesis warrants further studies considering the number of
the studied cases. Anyway, this hypothesis seems to be
reasonable, as, in the case of protein band 3 deficiency, fewer
vertical protein interactions may coexist with a normal
cytoskeleton, and, in the case of skeletal protein deficiency, a
fewer number of vertical interactions coexist with an almost
normal number of integral membrane proteins. It is known
that the pathway for the removal of senescent RBCs involves a
senescent neoantigen, which has been related to band 3 protein
(Kay et al, 1983). Clustering, proteolysis or even exposure of
unusual epitopes, trigger the binding of specific autoanti-band
3 antibodies and complement activation (Lutz et al, 1987;
Lutz, 1992), marking the cell for death.
While spectrin- and ankyrin-deficient RBCs escape
opsonisation by releasing band 3-containing vesicles with
increasing cell age, in the case of band 3-deficient RBCs they
do not lose band 3 with cell aging (Reliene et al, 2002).
Therefore, band 3 clusters required for the bivalent binding
of immunoglobulin (Ig)G naturally occurring anti-band 3
antibodies (Kay et al, 1991; Lutz, 1992) may further enhance
macrophage activation, which may condition erythropoiesis
in a different way.
Since EPO was cloned in 1985, recombinant human
erythropoietin (rHu-EPO) has been used for the treatment
of anaemia associated with renal failure, human immunode-
ficiency virus (HIV) infection in az(ido)t(hymidine) (AZT)-
treated patients, and chemotherapy (Cazzola et al, 1998;
Lacombe & Mayeux, 1998). Recently, it has also been
administered to infants with HS presenting a severe anaemia.
Most of them improved their response in achieving a
compensated haematological state (Tchernia et al, 2000; Schiff
et al, 2003); however, few of them did not reach sustained
transfusion-independence despite EPO therapy. Recently, it
was reported that chronic kidney disease patients may also
present resistance to EPO therapy (Macdougall, 2004) and that
patients who persistently failed to respond expressed abnor-
mally raised levels of the pro-inflammatory cytokines tumour
necrosis factor and interferon-gamma, which are known to
inhibit erythropoiesis. Further studies are warranted to clarify
the mechanism that may disturb the erythropoietic response in
these pathologies and in HS, as it may lead to the improvement
of new therapeutic strategies.
In conclusion, our data shows HS as a disease linked to an
overproduction of EPO in accordance with the severity of the
disease. Moreover, it suggests that further studies are warran-
ted to clarify the inhibition of the EPO response observed with
worsening of HS, and to clarify the erythropoietic response
according to the type of protein deficiency underlying the
disease.
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